Benjamin F. Edwards & Company, Inc. Acadia Pharmaceuticals Inc Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 1,012 shares of ACAD stock, worth $15,483. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,012
Previous 731
38.44%
Holding current value
$15,483
Previous $14,000
21.43%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ACAD
# of Institutions
288Shares Held
161MCall Options Held
723KPut Options Held
257K-
Baker Bros. Advisors LP New York, NY42.9MShares$656 Million9.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.7MShares$210 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY13.7MShares$210 Million3.72% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$185 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$88.8 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $2.48B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...